The Traderszone Network

Published in TZ Latest News 23 November, 2015 by The TZ Newswire Staff

BioMarin’s DMD Drug Faces Obstacles Tomorrow

An FDA advisory committee will consider the company’s therapy for Duchenne muscular dystrophy and its conclusions could impact competitor Sarepta Therapeutics.